Simulations Plus, Inc.

301 articles with Simulations Plus, Inc.

• DILIsym Awarded $1.5 Million Phase II NIH Grant

  1/17/2019

  Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months

• Simulations Plus Releases DDDPlus™ Version 6

  1/15/2019

  New models for in vitro systems lead to improved inputs for GastroPlus® simulations

• Simulations Plus to Present at the 21st Annual Needham Growth Conference

  1/10/2019

  Mr. O’Connor will host one-on-one meetings throughout the day at the conference which will be held at the Lotte New York Palace Hotel.

• Simulations Plus Reports First Quarter FY2019 Financial Results

  1/9/2019

  First quarter net revenues of $7.5 million reflecting 6.6% year over year growth

• Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results

  1/2/2019

  Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST

• Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018

  11/20/2018

  Simulations Plus, Inc. today announced that Shawn O’Connor, chief executive officer, and John Kneisel, chief financial officer, will present at the 11th Annual LD Micro Main Event investor conference at 9 a.m. PT on Tuesday, December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The conference will be held December 4-6, 2018.

• Simulations Plus Reports FY2018 and Fourth Quarter FY2018 Financial Results

  11/14/2018

  Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2018 fiscal year (FY18) and fourth quarter (4Q18) ended August 31, 2018.

• Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share Payable on November 8, 2018

  10/22/2018

  Simulations Plus, Inc. today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.06 per share of the Company’s common stock.

• Simulations Plus Receives New Grant Award from the FDA

  9/12/2018

  Incorporation of formulation characteristics into the GastroPlus™ mechanistic dermal absorption/PBPK model will inform regulatory decisions

• Simulations Plus Subsidiary DILIsym Awarded Grant for up to $1.7 Million For Model Development

  7/23/2018

  Novel in silico Drug-induced Kidney Injury Model

• Simulations Plus Enters Funded Research Collaboration with Large European Consortium

  7/18/2018

  Enhancements to mechanistic dermal absorption model in GastroPlus™ will target non-pharmaceutical markets

• Simulations Plus Reports Third Quarter FY2018 Financial Results

  7/10/2018

  Record quarter as revenues grow 26.7%, 9MoFY18 net income up 63.8%

• Simulations Plus to Report Third Quarter 2018 Financial Results

  7/3/2018

  Simulations Plus, Inc. announced that it will report its third quarter financial results for fiscal year 2018, the period ended May 31, 2018, after the close of the financial markets on Tuesday, July 10, 2018.

• Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018

  6/1/2018

  Will present on Tuesday, June 5, 2018, at 9:30 a.m. Pacific Time and hold one-on-one meetings with institutional investors throughout the day.

• Simulations Plus Releases GastroPlus™ Version 9.6

  5/23/2018

  Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 9.6 of its flagship PBPK modeling program, GastroPlus™.

• Simulations Plus Launches Version 2.0 of PKPlus

  2/1/2018

  Simulations Plus today announced the launch of version 2.0 of PKPlus, a major update to its software for analysis of preclinical and clinical trial data.

• Simulations Plus Subsidiary Cognigen Releases KIWI Version 2

  1/24/2018

  Cognigen today announced that it has released Version 2 of its KIWI Pharmacometric Communication and Collaboration Platform.

• Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share and Payable on February 2

  1/16/2018

  The cash dividend will be distributed on Friday, February 2, to shareholders of record as of Friday, January 26, 2018.

• DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym Version 7A

  1/11/2018

  DILIsym Services Inc. announced that it has released Version 7A of its flagship QSP (quantitative systems pharmacology) modeling program, DILIsym.

• Simulations Plus Reports First Quarter FY2018 Financial Results

  1/9/2018

  Simulations Plus today reported financial results for its first quarter of fiscal year 2018, the period ended November 30, 2017 (1QFY18).